{"id":164934,"date":"2023-01-18T00:35:50","date_gmt":"2023-01-18T05:35:50","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conference\/"},"modified":"2024-08-18T11:46:17","modified_gmt":"2024-08-18T15:46:17","slug":"cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conference","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conference.php","title":{"rendered":"CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference"},"content":{"rendered":"<p><![CDATA[SOUTH SAN FRANCISCO, Calif., Jan.  17, 2023  (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 19, 2023 at 2:30 p.m. ET.]]><\/p>\n<p>View post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/01\/17\/2590505\/0\/en\/CytomX-Therapeutics-to-Present-at-the-B-Riley-Securities-Virtual-Annual-Oncology-Investor-Conference.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference\">CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>View post: CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cytomx-therapeutics-to-present-at-the-b-riley-securities-virtual-annual-oncology-investor-conference.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-164934","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164934"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164934"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164934\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}